Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,683,608
  • Shares Outstanding, K 2,692,595
  • Annual Sales, $ 43,783 M
  • Annual Income, $ 7,382 M
  • 60-Month Beta 0.69
  • Price/Sales 2.24
  • Price/Cash Flow 9.42
  • Price/Book 3.67
Trade GSK with:

Options Overview

Details
  • Implied Volatility 20.69%
  • Historical Volatility 15.30%
  • IV Percentile 11%
  • IV Rank 11.31%
  • IV High 47.71% on 01/27/21
  • IV Low 17.25% on 03/22/21
  • Put/Call Vol Ratio 1.56
  • Today's Volume 1,892
  • Volume Avg (30-Day) 2,798
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 88,829
  • Open Int (30-Day) 83,974

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.69
  • Number of Estimates 3
  • High Estimate 0.89
  • Low Estimate 0.52
  • Prior Year 0.97
  • Growth Rate Est. (year over year) -28.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.32 +2.10%
on 03/15/21
36.80 -2.01%
on 03/29/21
+0.52 (+1.46%)
since 03/12/21
3-Month
33.53 +7.55%
on 02/26/21
39.31 -8.26%
on 01/26/21
-1.40 (-3.74%)
since 01/12/21
52-Week
33.26 +8.42%
on 10/30/20
43.18 -16.49%
on 05/13/20
-2.82 (-7.25%)
since 04/09/20

Most Recent Stories

More News
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail

Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.

REGN : 472.80 (-0.50%)
RHHBY : 41.5700 (-0.86%)
GSK : 36.06 (-1.61%)
VIR : 43.12 (-0.02%)
Keloid Treatment Market Research Report by Device, by Service, by Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19

Global share consists of several players including Pacific World Corporation, Revitol Corporation Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Novartis AG, Renovo Group plc., Valeant Pharmaceuticals...

AVMXY : 7.8900 (+9.13%)
BMY : 62.69 (+0.13%)
GALE : 0.26 (-7.14%)
GSK : 36.06 (-1.61%)
NVS : 87.34 (-0.24%)
PRGO : 40.52 (-0.02%)
SNOA : 8.10 (-5.70%)
VRX.TO : 30.80 (-3.33%)
World Acne Market Spotlight Report 2021: GlaxoSmithKline has the Highest Number of Completed Clinical Trials for Acne with 35 Trials

The "Market Spotlight: Acne" report has been added to ResearchAndMarkets.com's offering.

GSK : 36.06 (-1.61%)
BioSig Invited to Join Alliance for Artificial Intelligence in Healthcare (AAIH)

EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END

BSGM : 4.35 (-4.81%)
AMZN : 3,379.39 (+0.21%)
BAYN : 0.0100 (unch)
GE : 13.59 (-0.07%)
GSK : 36.06 (-1.61%)
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

DVAX : 10.07 (unch)
MRK : 76.22 (-0.12%)
GSK : 36.06 (-1.61%)
VBIV : 2.74 (-2.84%)
Marburg Hemorrhagic Fever Drug Market Report 2021 to 2027: Top Countries Data with Future Scope, Market Size, Share, Trends, Key Players, Drivers and Forecast

The latest report as Marburg Hemorrhagic Fever Drug Market acknowledges Size, Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, and Marburg Hemorrhagic Fever Drug Industry Share...

GSK : 36.06 (-1.61%)
IMV.TO : 3.55 (-1.93%)
SRPT : 69.38 (-1.64%)
Antiepileptic Drugs Market Augmented Expansion to be Registered by 2021-2025|Says Kenneth Research

Kenneth Research recently added a report on 'Antiepileptic Drugs Market’ in its database of market research reports which provides its readers an in-depth analysis on the latest trends, growth opportunities...

ABT : 121.04 (+0.12%)
GSK : 36.06 (-1.61%)
NVS : 87.34 (-0.24%)
PFE : 36.97 (+1.01%)
VRX.TO : 30.80 (-3.33%)
3 Must-Own High-Yield Pharmaceutical Stocks to Add to Your Portfolio

The pharmaceutical industry has remained a highly coveted industry since the onset of the COVID-19 pandemic. With dividend-paying biopharma stocks increasing their payouts to remain competitive amid rising...

ABBV : 108.25 (+0.66%)
GSK : 36.06 (-1.61%)
GILD : 64.66 (-0.69%)
Cell Culture Market Size to Reach USD 45.12 Billion in 2027 | Rising Demand for Monoclonal Antibodies, Growing Preference for Customized Therapies are Some Major Factors Driving Industry Growth, says Emergen Research

The global cell culture market size is expected to reach USD 45.12 Billion in 2027 and register a robust CAGR of 10.3% over the forecast period, according to the latest report by Emergen Research. Rising...

GSK : 36.06 (-1.61%)
Anti-Fungal Agents Market Growth, Latest Trend and Forecast 2021 - 2028 By Ameco Research

pune, India, Wed, 07 Apr 2021 23:37:44 / Comserve Inc. / -- The global Anti-Fungal Agents market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other...

ALPMF : 14.7000 (-0.64%)
BAYRY : 15.8100 (-0.66%)
ENZN : 0.7655 (-1.86%)
GSK : 36.06 (-1.61%)
MFAC : 14.76 (-0.74%)
MRK : 76.22 (-0.12%)
NVS : 87.34 (-0.24%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

3rd Resistance Point 36.36
2nd Resistance Point 36.28
1st Resistance Point 36.17
Last Price 36.06
1st Support Level 35.98
2nd Support Level 35.90
3rd Support Level 35.79

See More

52-Week High 43.18
Fibonacci 61.8% 39.39
Fibonacci 50% 38.22
Fibonacci 38.2% 37.05
Last Price 36.06
52-Week Low 33.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar